Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge

被引:47
|
作者
Manohar, Sandhya [1 ]
Ghamrawi, Ranine [1 ]
Chengappa, Madhuri [5 ]
Goksu, Busra N. Bacik [6 ]
Kottschade, Lisa [2 ]
Finnes, Heidi [3 ]
Dronca, Roxana [7 ]
Leventakos, Konstantinos [2 ]
Herrmann, Joerg [4 ]
Herrmann, Sandra M. [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, 200 First St SW, Rochester, MN 55902 USA
[2] Mayo Clin, Dept Med Oncol, Rochester, MN 55902 USA
[3] Mayo Clin, Dept Pharm, Rochester, MN 55902 USA
[4] Mayo Clin, Dept Cardiol, Rochester, MN 55902 USA
[5] Nazareth Hosp, Dept Internal Med, Philadelphia, PA USA
[6] Univ Texas Southwestern, Dept Psychiat, Dallas, TX USA
[7] Mayo Clin, Dept Med Oncol, Jacksonville, FL 32224 USA
来源
KIDNEY360 | 2020年 / 1卷 / 01期
关键词
Acute Kidney Injury and ICU Nephrology; Acute Interstitial Nephritis; Acute Kidney Injury; Biopsy; Cohort Studies; Creatinine; Immune check point-rechallenge; Immune checkpoint inhibitors; Immune-related adverse event; Immunotherapy; Kidney Function Tests; Pneumonia; Prednisone; Proton Pump Inhibitors; COMBINED NIVOLUMAB; RENAL-FUNCTION; ASSOCIATION; IPILIMUMAB; RECOVERY; FEATURES;
D O I
10.34067/KID.0000152019
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background The objective of this case cohort study was to describe our experience in the care of patients with immune checkpoint inhibitor-related acute interstitial nephritis (ICI-AIN) including rechallenge. Methods A descriptive case series of patients that received an ICI and had an AKI (defined as a >= 1.5-fold increase in serum creatinine) as an immune-related adverse event (irAE), with biopsy-proven or clinically suspected ICI-AIN from January 1, 2014 to December 1, 2018 at Mayo Clinic, Rochester. We studied details regarding diagnosis, clinical course, management, and outcomes of rechallenge of immunotherapy. Complete response (CR) was defined as return of kidney function back to baseline or < 0.3 mg/dl above baseline creatinine; partial response (PR) was defined as creatinine > 0.3 mg/dl from baseline, but less than twofold above the baseline by the end of steroid course. Results A total of 14 cases of biopsy-proven (35%) or clinically suspected (65%) ICI-AIN was identified. All patients had their ICI withheld and 12 patients received steroids. Steroid regimens were highly variable. The starting equivalent dose of prednisone was higher in those that had a CR versus a PR (median 0.77 mg/kg versus 0.66 mg/kg). Proton pump inhibitors (PPIs) were used in 11 patients and were stopped in eight (73%) patients at the time of the AKI event. A CR was seen in five (63%) of the eight patients who discontinued PPIs. Rechallenge was attempted in four of the 14 patients: three were successful with no recurrence of AKI, but one patient had recurrent AKI and fatal pneumonitis. Conclusions Careful review, withholding ICI and concomitant known AIN-inducing medications, along with prompt initial steroid management were the key in complete renal kidney recovery. A kidney biopsy should be strongly considered. Rechallenge of immunotherapy after a kidney irAE, although challenging, is possible and would need careful evaluation on an individual basis.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 50 条
  • [31] IMMUNE CHECKPOINT INHIBITOR (ICI) INDUCED RELAPSING INTERSTITIAL NEPHRITIS
    Savedchuk, Solomiia
    Mando, Ramy
    Faieta, Antonio
    Dancik, Tavis
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (05) : 731 - 731
  • [32] Acute interstitial nephritis (AIN) following immune checkpoint inhibitor (ICI) therapy in metastatic RCC (mRCC) as a potential predictor of response
    Patel, Viral M.
    Elias, Roy
    Formella, Joseph
    Schwartzman, William
    Christie, Alana
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Severe acute interstitial nephritis/nephrotoxicity during BRAF and MEK inhibitor therapy
    Rauschenberg, R.
    Gellrich, F. F.
    Garzarolli, M.
    Tonnus, W.
    Paliege, A.
    Meier, F.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 91 - 91
  • [34] Risk of Acute Interstitial Nephritis in Patients on Chronic Proton Pump Inhibitor Therapy
    Trujillo, Sophie
    Desai, Aakash
    Dalal, Shaman
    Sandhu, Dalbir S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S676 - S676
  • [35] Acute interstitial nephritis: aetiology and management
    Schurder, Juliet
    Buob, David
    Perrin, Peggy
    Thervet, Eric
    Karras, Alexandre
    Hertig, Alexandre
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (10) : 1799 - 1802
  • [36] Diagnosis and management of acute interstitial nephritis
    Kodner, CM
    Kudrimoti, A
    AMERICAN FAMILY PHYSICIAN, 2003, 67 (12) : 2527 - 2534
  • [37] Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience
    Xiao, Junjuan
    Li, Xingyu
    Wang, Xuan
    Guan, Yaping
    Liu, Hairong
    Liang, Jing
    Li, Yan
    Wang, Baocheng
    Wang, Jun
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [38] Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
    Mamlouk, Omar
    Selamet, Umut
    Machado, Shana
    Abdelrahim, Maen
    Glass, William F.
    Tchakarov, Amanda
    Gaber, Lillian
    Lahoti, Amit
    Workeneh, Biruh
    Chen, Sheldon
    Lin, Jamie
    Abdel-Wahab, Noha
    Tayar, Jean
    Lu, Huifang
    Suarez-Almazor, Maria
    Tannir, Nizar
    Yee, Cassian
    Diab, Adi
    Abudayyeh, Ala
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [39] Infliximab for Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis: A Biomarker-Guided Approach
    Barbir, Elena-Bianca
    Koirala, Priscilla
    Gutierrez, Luis Eduardo
    Herrmann, Sandra
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [40] DRUG-INDUCED ACUTE INTERSTITIAL NEPHRITIS
    DIAZ, JM
    CALERO, F
    GUIRADO, L
    BALLARIN, JA
    BARCELO, P
    NEFROLOGIA, 1994, 14 (05): : 580 - 583